

Alla S Salasyuk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5559815/publications.pdf>

Version: 2024-02-01

63
papers

2,714
citations

1162889

8
h-index

302012

39
g-index

68
all docs

68
docs citations

68
times ranked

2956
citing authors

#	ARTICLE	IF	CITATIONS
1	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 121-130.	6.3	1,625
2	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 723-732.	13.9	480
3	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 131-138.	6.3	394
4	Randomized Trial of Perindopril, Enalapril, Losartan and Telmisartan in Overweight or Obese Patients with Hypertension. <i>Clinical Drug Investigation</i> , 2013, 33, 553-561.	1.1	52
5	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". <i>Obesity and Metabolism</i> , 2021, 18, 5-99.	0.4	49
6	The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 101-109.	0.2	16
7	NATIONAL CLINICAL RECOMMENDATIONS FOR OBESITY: CONCEPT AND PROSPECTS. , 2017, 61, 134-140.		12
8	Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I. <i>Russian Journal of Cardiology</i> , 2021, 26, 4368.	0.4	10
9	Effectiveness of insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs. <i>Russian Journal of Cardiology</i> , 2019, , 70-79.	0.4	10
10	OPTIMAL ORGANOPROTECTION, CONTROL OF BLOOD PRESSURE AND METABOLIC DISORDER WITH THE FIXED COMBINATION OF LISINAPRIL, AMLODIPINE AND ROSUVASTATIN IN SYSTEMIC HYPERTENSION. <i>Russian Journal of Cardiology</i> , 2018, , 49-55.		7
11	EFFECTS OF MELATONIN ON BLOOD PRESSURE, ENDOTHELIAL FUNCTION AND VASCULAR STIFFNESS IN PATIENTS WITH METABOLIC SYNDROME AND SLEEP DISORDERS. <i>Arterial Hypertension (Russian) Tj ETQq1 1 0.784314 rgBT Overlo</i>		
12	Identifying Early Vascular Ageing in Patients With Metabolic Syndrome: Unresolved Issues and a Proposed Novel VAMets Score. <i>Heart Lung and Circulation</i> , 2021, 30, 1752-1761.	0.2	4
13	Pharmacoeconomic analysis of the use of dapagliflozin in patients with NYHA class II-IV chronic heart failure with reduced left ventricular ejection fraction $\leq 40\%$ in the Russian Federation. <i>Consilium Medicum</i> , 2020, 22, 45-51.	0.1	4
14	Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm. <i>Farmakoekonomika</i> , 2021, 13, 377-387.	0.4	3
15	The effect of various classes of glucose-lowering medications on the blood vessel elasticity in patients with type 2 diabetes. <i>Russian Journal of Cardiology</i> , 2020, 25, 3766.	0.4	3
16	Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin. <i>Systemic Hypertension</i> , 2018, 15, 24-31.	0.1	3
17	Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part II. <i>Russian Journal of Cardiology</i> , 2022, 27, 4759.	0.4	3
18	CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 45-50.	0.3	2

#	ARTICLE	IF	CITATIONS
19	SLOW RELEASE MELATONINE IN METABOLIC SYNDROME SYMPTOMATIC CORRECTION. Russian Journal of Cardiology, 2016, , 61-67.	0.4	2
20	COMPARATIVE EFFECTIVENESS OF FIXED-DOSE COMBINATIONS OF LISINAPRIL/AMLODIPINE AND ENALAPRIL/HYDROCHLOROTHIAZIDE. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 25-29.	0.4	2
21	Metabolic syndrome and kidney: nephroprotection and reduction of cardiovascular risk. Arterial Hypertension (Russian Federation), 2018, 24, 369-378.	0.1	2
22	Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria. Farmakoeconomika, 2019, 12, 72-84.	0.4	2
23	Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration. Rossiiskii Oftal'mologicheskii Zhurnal, 2020, 13, 42-50.	0.1	2
24	Optimization of blood pressure control, organ protection and metabolic disorders using a fixed-dose combination of lisinopril+amlodipine+rosuvastatin in hypertensive patients after COVID-19. Russian Journal of Cardiology, 2022, 26, 4766.	0.4	2
25	Early vascular aging in patients with metabolic syndrome: features of the course and diagnosis. <i>Arkhivno-Rossiiskii Zhurnal Terapevticheskoi Praktiki</i> , 2021, 2, 50-62.	0.1	1
26	ADDITIONAL ANGIOPROTECTION AND METABOLIC DISORDERS CORRECTION IN TREATMENT OF ARTERIAL HYPERTENSION PATIENTS REACHED TARGET BLOOD PRESSURE LEVELS, WITH FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE. Russian Journal of Cardiology, 2018, , 67-74.	0.4	1
27	Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors. Russian Journal of Cardiology, 2020, 25, 3767.	0.4	1
28	Optimization of Blood Pressure Control, Metabolic Parameters, and Target Organs Protection with Perindopril + Indapamide Fixed Combination in Hypertensive Patients with Obesity and Prediabetes. Diabetes, 2018, 67, 129-LB.	0.3	1
29	Effect of angiotensin II receptor antagonists on left ventricular hypertrophy, vascular elasticity, and lipid and carbohydrate metabolic parameters in metabolic syndrome. Systemic Hypertension, 2013, 10, 27-33.	0.1	1
30	Effects of Testosterone Replacement Therapy on Cardio-Metabolic, Hormonal and Anthropometric Parameters in Obese Hypogonadal Men with Metabolic Syndrome. Obesity, Open Access, 2015, 1, .	0.1	1
31	The influence of fixed-dose combination of amlodipine and bisoprolol on vascular elasticity in patients with arterial hypertension. Consilium Medicum, 2015, 17, 19-22.	0.1	1
32	Losartan versus Telmisartan in Overweight Patients with Arterial Hypertension. Journal of Advanced Clinical Pharmacology, 2015, 2, 1-7.	0.5	1
33	Possibilities of indapamide for angioprotection in patients with metabolic syndrome following treatment with thiazide-containing combinations. Russian Heart Journal, 2016, 15, 192-196.	0.1	1
34	Blood pressure control and vascular protection with a fixed-dose combination of lisinopril + amlodipine + rosuvastatin in hypertensive patients. Vessel Plus, 2018, 2, 37.	0.4	1
35	Pharmacoeconomic rationale for alirocumab administration in acute coronary syndrome. Military Thought, 2019, 28, 99-104.	0.1	1
36	Optimal Organ Protection and Blood Pressure Control with the Single Pill Combination Lisinopril, Amlodipine and Indapamide in Arterial Hypertension. Rational Pharmacotherapy in Cardiology, 2020, 16, 931-937.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Clinical and economic aspects of bulevirtide use in patients with chronic hepatitis D. <i>Infektsionnye Bolezni</i> , 2020, 18, 104-111.	0.2	1
38	Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts. <i>Russian Journal of Cardiology</i> , 2022, 26, 4791.	0.4	1
39	Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia. <i>Journal of Modern Oncology</i> , 2021, 23, 612-620.	0.1	1
40	Prevalence of metabolic syndrome and testosterone replacement therapy in men with andropause. <i>Maturitas</i> , 2015, 81, 212.	1.0	0
41	The quality of life for women in a period of menopause. <i>Maturitas</i> , 2015, 81, 178.	1.0	0
42	PRM101 - THE COST BURDEN OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN RUSSIAN FEDERATION. <i>Value in Health</i> , 2018, 21, S373.	0.1	0
43	PRS4 HEALTH TECHNOLOGY ASSESSMENT OF DUPILUMAB IN SEVERE BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S77.	0.5	0
44	Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 119-127.	0.1	0
45	Resolution of an online meeting of the Siberian, Far Eastern and Southern Federal Districts experts on the results of the EMPEROR-Reduced trial – Therapeutic approaches in heart failure with reduced ejection fraction: the EMPA-REG OUTCOME trial and the EMPEROR-Reduced trial. <i>Complex Issues of Cardiovascular Diseases</i> , 2021, 10, 121-129.	0.3	0
46	Improving the efficacy of antihypertensive therapy with the use of fixed-dose combination therapy. <i>Arterial Hypertension (Russian Federation)</i> , 2011, 17, 513-517.	0.1	0
47	Sravnitel'naya effektivnost' perindopriila i telmisartana u patsientov s arterial'noy gipertenziei i ozhireniem. <i>Systemic Hypertension</i> , 2012, 9, 33-39.	0.1	0
48	The abilities of losartan in angioprotection in hypertensive patients with hyperuricemia. <i>Systemic Hypertension</i> , 2012, 9, 16-21.	0.1	0
49	Comparative analysis of the efficiency of the selective b-blocker nebivolol and the angiotensin II receptor blocker valsartan in men with hypertension, metabolic syndrome, and erectile dysfunction. <i>Cardiosomatics</i> , 2013, 4, 57-66.	0.2	0
50	Self-management of diabetes. <i>Cardiosomatics</i> , 2013, 4, 17-20.	0.2	0
51	WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN. <i>Russian Journal of Cardiology</i> , 2016, , 70-75.	0.4	0
52	COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN. <i>Farmakoeconomika</i> , 2016, 9, 58-68.	0.4	0
53	The possibility of perindopril in angioprotective in patients with metabolic syndrome after combination therapy with a thiazide diuretic. <i>Systemic Hypertension</i> , 2016, 13, 30-33.	0.1	0
54	Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis. <i>Sovremennaya Revmatologiya</i> , 2017, 11, 88-95.	0.1	0

#	ARTICLE	IF	CITATIONS
55	The Influence of Empagliflozin on Vascular Age and Key Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients. Doctor Ru, 2018, 152, 6-11.	0.1	0
56	Pharmacoeconomic Analysis of Tiotropium Bromide and Olodaterol Fixed Combination as Maintenance Therapy in Patients with Chronic Obstructive Pulmonary Disease in Russian Federation. Medical Technologies Assessment and Choice (ÐœÐ¼Ð'Ð,Ñ†Ð,Ð½Ð°Ð,Ð¼ Ñ,Ð¼Ñ...Ð½Ð¾Ð»Ð»Ð¾Ð³Ð, Ð½Ð†Ð¼Ð½Ð°Ð° Ð, Ð²ÑÐ±Ð¾Ð»), 2019, 10, 22-25.	0.1	0
57	Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis. Oncogematologiya, 2019, 14, 98-108.	0.1	0
58	Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation. Farmakoeconomika, 2020, 13, 101-111.	0.4	0
59	Early vascular aging risk assessment in patients with metabolic syndrome. European Heart Journal, 2020, 41, .	1.0	0
60	Budget impact analysis of ertugliflozin in patients with type 2 diabetes mellitus who failed to achieve glycemic targets on metformin. ÂndokrinologiÂ Novosti, MneniÂ, ObuÂenie, 2021, 10, 33-43.	0.0	0
61	Blood pressure control, target organ protection and metabolic disorders control using a fixed combination of azilsartan medoxomil + chlorthalidone in hypertensive patients survived after severe and extremely severe COVID-19. Arterial Hypertension (Russian Federation), 2022, 27, 642-652.	0.1	0
62	Clinical and economic analysis of using dapagliflozin in patients with chronic kidney disease in the Russian Federation. Consilium Medicum, 2021, 23, 932-938.	0.1	0
63	Pharmacoeconomic analysis of ferric carboxymaltose in patients with chronic heart failure and iron deficiency in the Russian Federation. , 2022, , 30-43.		0